<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medtronic Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/medtronic-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(STJ) St. Jude Medical Build on Alliance with Abbott Laboratories</title>
		<link>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648</link>
		<comments>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:03:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[FFR]]></category>
		<category><![CDATA[First Trust FTSE EPRA-NAREIT Glb Real Es]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99648</guid>
		<description><![CDATA[St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott&#8217;s drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. Both companies have agreed to endorse each other’s products to their respective customers. Further, Abbott has received the rights to promote St. Jude’s RadiAnalyze Xpress Measurement System and the ILUMIEN PCI Optimization System. This alliance is expected to benefit patient outcomes, as doctors will be able to combine Abbott’s XIENCE family of stents with St. Jude’s optical coherence tomography (OCT) and fractional flow reserve (FFR) know-how to widen the scope of clinical treatments. Abbott Laboratories is a global manufacturer of a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IART) Integra LifeScience Holdings Corporation Earns FDA Nod for Spine Device</title>
		<link>http://www.stockbloghub.com/2012/04/23/iart-integra-lifescience-holdings-corporation-earns-fda-nod-for-spine-device/99408</link>
		<comments>http://www.stockbloghub.com/2012/04/23/iart-integra-lifescience-holdings-corporation-earns-fda-nod-for-spine-device/99408#comments</comments>
		<pubDate>Mon, 23 Apr 2012 15:31:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[IART]]></category>
		<category><![CDATA[Integra LifeSciences Holdings Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99408</guid>
		<description><![CDATA[Global provider of surgical implants and medical instruments, Integra LifeScience Holdings Corporation (IART) recently received the 510(k) clearance from the US Food and Drug Administration (FDA) for its path-breaking Integra Vu aPOD Prime Inter-vertebral Body Fusion Device (IBD), a zero profile IBD designed for anterior lumbar fusion (ALIF) procedures. The company also showcased the product at the annual meeting of the American Association of Neurological Surgeons held between April 14 &#8211; 18, 2012 in Florida. IBDs are small, hollow spinal implants that provide stability for spinal fusion after the surgical removal of a diseased lumbar disc. To restore the physiological disc height and allow fusion between vertebral bodies, these particles are inserted into the inter-vertebral space. While conventionally surgeons need supplemental fixation to hold the IBD in place, this new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/23/iart-integra-lifescience-holdings-corporation-earns-fda-nod-for-spine-device/99408/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Beats The Street &#8211; Raises Guidance</title>
		<link>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962</link>
		<comments>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962#comments</comments>
		<pubDate>Fri, 20 Apr 2012 17:26:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=98962</guid>
		<description><![CDATA[St. Jude Medical, Inc. (STJ), a large-cap medical devices and technology development company, reported first quarter fiscal 2012 adjusted earnings of 86 cents beating the Zacks Consensus Estimate of 83 cents per share and surpassing the year-ago earnings of 80 cents per share. Adjusted earnings exclude extraordinary and one-time charges such as restructuring expenses to modernize manufacturing in the Cardiac Rhythm Management (CRM) segment. In the reported quarter, profit dropped 9% to $212 million (or 67 cents a share). Revenues St. Jude reported net revenues of $1,395 million, up 1% year over year, beating the Zacks Consensus Estimate of $1,383 million. Net sales rose 2% on constant currency basis. Healthy growth across the company’s smaller Atrial Fibrillation (AF) and Neuromodulation segments were largely offset by the decline in the core ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611</link>
		<comments>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:13:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94611</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609</link>
		<comments>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609#comments</comments>
		<pubDate>Thu, 08 Mar 2012 19:28:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94609</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Buying NeuroNexus</title>
		<link>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142</link>
		<comments>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142#comments</comments>
		<pubDate>Thu, 23 Feb 2012 19:36:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=92142</guid>
		<description><![CDATA[Medical technology company Greatbatch (GB) is acquiring Michigan-based implantable medical device design firm NeuroNexus Technologies for roughly $12 million. The deal includes assumption of debt and future considerations (undisclosed). NeuroNexus, founded in 2004, specializes in high-value neural interface technology, components and systems for neuroscience and clinical markets. The entity possesses a vast portfolio of intellectual property, core technologies and capabilities to facilitate the development of innovative neural interface devices across a broad range of functions including neuromodulation, optical stimulation and targeted drug delivery applications. The acquisition is expected to boost Greatbatch’s foothold across cardiovascular and neuromodulation markets. The pooling of NeuroNexus’ technologies and Greatbatch’s capabilities will enable the combined entity to provide new world-class research products and systems to neuroscientists across the globe. Greatbatch expects the acquisition to be non-dilutive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Fourth Quarter 2011 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302</link>
		<comments>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:32:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91302</guid>
		<description><![CDATA[Medical devices major St. Jude Medical’s (STJ) fourth-quarter 2011 adjusted earnings per share of 86 cents beat the Zacks Consensus Estimate by a couple of cents and exceeded the year-ago earnings of 75 cents. Highlights from the Quarter Profit (as reported) for the fourth quarter slipped roughly 21% year over year to $163.4 million (or 51 cents a share) as higher sales were overshadowed by lofty special charges. Revenues rose 4% year over year to $1,406.9 million, beating the Zacks Consensus Estimate of $1,400 million. Double-digit growth across the company’s Atrial Fibrillation, Cardiovascular and Neuromodulation segments was partly masked by the decline in the core Cardiac Rhythm Management (“CRM”) division. Revenues from the CRM division fell 4% year over year, indicating sustained softness in the U.S. ICD market. ICD revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) New Year Bets from MedTech</title>
		<link>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062</link>
		<comments>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062#comments</comments>
		<pubDate>Fri, 06 Jan 2012 21:03:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89062</guid>
		<description><![CDATA[Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean. The U.S. economy continues to be cramped by a spate of headwinds including a still unstable job market, high debt, a soft housing sector and last but surely not the least, the European sovereign debt contagion, which have hit industries across the board. The recent EU summit did not bring out any concrete solution to staunch the debt crisis which began in Greece in 2009. The healthcare sector, traditionally revered as a safe haven for investors and one of the most preferred areas to take cover in the midst of market volatility, has been somewhat proved not immune to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam States Preclinical Data</title>
		<link>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523</link>
		<comments>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523#comments</comments>
		<pubDate>Tue, 03 Jan 2012 19:15:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89523</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington&#8217;s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington&#8217;s disease. Further, ALN-HTT was well tolerated in these studies. ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food &#38; Drug Administration (FDA) will allow the candidate to enter early stage clinical trials. Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) Christmas Gift for the Ailing Heart</title>
		<link>http://www.stockbloghub.com/2011/12/14/stj-christmas-gift-for-the-ailing-heart/87908</link>
		<comments>http://www.stockbloghub.com/2011/12/14/stj-christmas-gift-for-the-ailing-heart/87908#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:48:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87908</guid>
		<description><![CDATA[Wilson Greatbatch, the self-professed &#8220;humble tinkerer&#8221; and a trailblazer in medical technology, invented the first implantable cardiac pacemaker in 1958 which kept the rhythm of millions of heartbeats and preserved countless lives across the planet. A couple of decades later, the first patient received an implantable defibrillator, the brainchild of Dr. Michel Mirowski, in 1980. But that took place decades ago and we have come a long way since then. Medical technology has advanced by leaps and bounds, revolutionizing the way medicine is practiced, in a hi-tech world. And what is more quintessential in this Faustian quest for good, and even better health, than taking care of the heart? There is a Chinese proverb that goes: “If you keep a green bough in your heart, the singing bird will come.” ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/stj-christmas-gift-for-the-ailing-heart/87908/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific Corporation Grows US Cardiac Rhythm Management Portfolio</title>
		<link>http://www.stockbloghub.com/2011/12/02/bsx-boston-scientific-corporation-grows-us-cardiac-rhythm-management-portfolio/87918</link>
		<comments>http://www.stockbloghub.com/2011/12/02/bsx-boston-scientific-corporation-grows-us-cardiac-rhythm-management-portfolio/87918#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:29:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[DES]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[WisdomTree SmallCap Dividend]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87918</guid>
		<description><![CDATA[Boston Scientific Corporation’s (BSX) Cardiac Rhythm Management (CRM) should record higher sales with the US Food and Drug Administration (FDA) approving Incepta, Energen and Punctua cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). These devices are meant to treat heart failure and sudden cardiac death. Though expected, the US approval comes even earlier than the company’s original guidance of late 2011 or early 2012. CE Mark approval for these defibrillators was received in the second quarter of 2011. The company is confident of the ready adoption of these devices as they come with improved therapy options, advanced battery longevity and a DF4 universal connector system. The company also announced an extended warranty for these devices in the US and many international countries of up to 10 years. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/bsx-boston-scientific-corporation-grows-us-cardiac-rhythm-management-portfolio/87918/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZOLL) ZOLL Medical&#8217;s AutoPulse Tapped by WSPR Szczecin</title>
		<link>http://www.stockbloghub.com/2011/11/30/zoll-zoll-medicals-autopulse-tapped-by-wspr-szczecin/87705</link>
		<comments>http://www.stockbloghub.com/2011/11/30/zoll-zoll-medicals-autopulse-tapped-by-wspr-szczecin/87705#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:57:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87705</guid>
		<description><![CDATA[Resuscitation devices maker ZOLL Medical (ZOLL) said that its new AutoPulse Plus cardiac support pumps has been bought by WSPR Szczecin, the biggest emergency service operator in Poland. The Polish entity has purchased 49 such devices to equip its fleet of ambulances. The innovative AutoPulse Plus pumps enables rescuers to defibrillate without stopping chest compressions for defibrillation. WSPR Szczecin selected the device based on positive user experience following a 12-month evaluation. The Massachusetts-based company also noted that WSPR Szczecin has initiated a program to upgrade to its new E Series Monitor/Defibrillator from the existing M Series platform. The E Series connects directly to AutoPulse Plus, which enables real-time integrated operation of these devices, thereby allowing consistent, uninterrupted chest compressions with timed shock delivery. Chest compressions, if stopped during defibrillation, results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/zoll-zoll-medicals-autopulse-tapped-by-wspr-szczecin/87705/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic 2012 Second Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/11/28/mdt-medtronic-2012-second-quarter-earnings-scorecard/87649</link>
		<comments>http://www.stockbloghub.com/2011/11/28/mdt-medtronic-2012-second-quarter-earnings-scorecard/87649#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:34:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87649</guid>
		<description><![CDATA[The announcement of Medtronic’s (MDT) second quarter fiscal 2012 results, as on November 22, 2011, has led analysts to revise their estimates lower for the third quarter although the situation improves for the current fiscal. Second Quarter Highlights Medtronic reported an adjusted EPS of 84 cents in the second quarter of fiscal 2012, a couple of cents above the Zacks Consensus Estimate and the year-ago quarter. Revenues were $4.132 billion in the quarter, up 6% (up 3% at constant exchange rates or CER) year over year and higher than the Zacks Consensus Estimate of $4.066 billion. The company recorded 44% of its total sales from the international market during the quarter, which climbed 14% year over year (6% at CER) to reach $1.832 billion. As a result of the company’s focus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/mdt-medtronic-2012-second-quarter-earnings-scorecard/87649/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Earns FDA OK on Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/11/10/ew-edwards-lifesciences-earns-fda-ok-on-trial-enrollment/86853</link>
		<comments>http://www.stockbloghub.com/2011/11/10/ew-edwards-lifesciences-earns-fda-ok-on-trial-enrollment/86853#comments</comments>
		<pubDate>Thu, 10 Nov 2011 21:23:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86853</guid>
		<description><![CDATA[Recently, Edwards Lifesciences Corporation (EW) received conditional approval from the US Food and Drug Administration for enrollment of a certain group of patients in the PARTNER II trial. The trial is studying the company’s next-generation Sapien XT transcatheter heart valve (THV). Under the new cohort (PARTNER II Cohort A) of the trial, patients (up to 2,000) with severe, symptomatic aortic valve stenosis, who are at higher risk of traditional open heart surgery, will be enrolled. They will be randomized to undergo either surgery or receive transcatheter valve replacement with Sapien XT (delivered either transfemorally or transapically). The primary endpoints will be a combination of mortality rate and major stroke at two years while valve performance and quality-of-life will be considered as secondary endpoints. The first cohort of the trial (PARTNER ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/10/ew-edwards-lifesciences-earns-fda-ok-on-trial-enrollment/86853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Analyst Raises Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/11/06/gb-greatbatch-analyst-raises-shares-to-outperform/86509</link>
		<comments>http://www.stockbloghub.com/2011/11/06/gb-greatbatch-analyst-raises-shares-to-outperform/86509#comments</comments>
		<pubDate>Sun, 06 Nov 2011 20:47:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86509</guid>
		<description><![CDATA[We upgrade our recommendation on Greatbatch (GB) to Outperform following its impressive third-quarter 2011 results. Adjusted earnings of 41 cents for the quarter outstripped the Zacks Consensus Estimate of 34 cents. Profit surged 17% year over year. Sales rose 3% year over year to $131.7 million, matching the Zacks Consensus Estimate. Revenues and profit were boosted by double-digit growth across the company’s Orthopedic and Vascular franchises, which offset the decline in the Electrochem unit. The company backed its revenue and earnings forecast for the full year. Greatbatch is a leading producer and supplier of batteries, capacitors and components used in implantable medical devices. The company’s top customers include Boston Scientific (BSX), Johnson &#38; Johnson (JNJ), Medtronic (MDT) and St. Jude (STJ). Greatbatch has been acquiring complementary businesses over the last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/06/gb-greatbatch-analyst-raises-shares-to-outperform/86509/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Third Quarter 2011 Earnings Helped By Medical Business</title>
		<link>http://www.stockbloghub.com/2011/11/02/gb-greatbatch-third-quarter-2011-earnings-helped-by-medical-business/86281</link>
		<comments>http://www.stockbloghub.com/2011/11/02/gb-greatbatch-third-quarter-2011-earnings-helped-by-medical-business/86281#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:02:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86281</guid>
		<description><![CDATA[Greatbatch’s (GB) third-quarter fiscal 2011 adjusted (excluding one-time items) earnings per share of 41 cents outpaced both the Zacks Consensus Estimate and the year-ago adjusted earnings of 34 cents. Profit (as reported) soared 17% year over year to roughly $7 million (or 30 cents a share) owing to healthy sales from the New York-based company’s Orthopedic and Vascular businesses, supported by lower interest expense and tax. Revenues Revenues rose 3% year over year to $131.7 million, in line with the Zacks Consensus Estimate. Double-digit growth across the Orthopedic and Vascular franchises masked a decline in the Electrochem division. Foreign currency movements contributed $2 million to orthopedic revenues in the quarter. Segment Review Sales from the larger Greatbatch Medical division rose 6% year over year to $113.3 million as the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/gb-greatbatch-third-quarter-2011-earnings-helped-by-medical-business/86281/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences 2011 Fourth Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/10/31/ew-edwards-lifesciences-2011-fourth-quarter-earnings-scorecard/86162</link>
		<comments>http://www.stockbloghub.com/2011/10/31/ew-edwards-lifesciences-2011-fourth-quarter-earnings-scorecard/86162#comments</comments>
		<pubDate>Mon, 31 Oct 2011 15:47:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86162</guid>
		<description><![CDATA[The announcement of Edwards Lifesciences’ (EW) third quarter fiscal 2011 results as on October 19, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011. Third Quarter Highlights Edwards reported an adjusted EPS of 38 cents in the third quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, and missing the year-ago quarter’s adjusted EPS of 43 cents. Revenues increased 18.3% to $412.7 million, exceeding the Zacks Consensus Estimate of $405 million. Heart Valve Therapy remained the strongest segment at Edwards with an annualized growth of 22.7% to reach $246.1 million. Sales of surgical heart valves grew 7.7% to $163.5 million and transcatheter heart valves (THV) catapulted 69.1% to book $82.6 million. The other segments of the company, namely Critical Care, Cardiac Surgery ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/31/ew-edwards-lifesciences-2011-fourth-quarter-earnings-scorecard/86162/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Corporation Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/18/ew-edwards-lifesciences-corporation-earnings-preview/85251</link>
		<comments>http://www.stockbloghub.com/2011/10/18/ew-edwards-lifesciences-corporation-earnings-preview/85251#comments</comments>
		<pubDate>Tue, 18 Oct 2011 17:11:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>
		<category><![CDATA[STS]]></category>
		<category><![CDATA[Supreme Industries Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85251</guid>
		<description><![CDATA[Edwards Lifesciences Corporation (EW) is scheduled to release its third quarter fiscal 2011 results on Wednesday, October 19, 2011 after the market closes. The company is expected to earn 39 cents per share during the quarter on $405 million in revenues, according to the Zacks Consensus Estimate. The consensus estimate is lower that the year-ago quarter’s EPS of 43 cents. As per Edwards’ guidance (provided along with the second quarter results), adjusted EPS is expected in the range of 37?39 cents. Previous Quarter Highlights Edwards reported an adjusted EPS of 49 cents in the second quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, although exceeding the year-ago quarter’s adjusted EPS of 46 cents. Revenues increased 18.1% to $431.2 million, also ahead of the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/18/ew-edwards-lifesciences-corporation-earnings-preview/85251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757#comments</comments>
		<pubDate>Thu, 06 Oct 2011 23:38:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84757</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to evaluate the safety and tolerability of the candidate in patients suffering from high low-density lipoprotein cholesterol (LDLc or “bad” cholesterol). Moreover, the clinical activity of ALN-PCS is also expected to be assessed through the study on the basis of measurements of plasma PCSK9 protein and serum LDLc. Results from the study, which is being conducted in the UK, are expected by year end. ALN-PCS is a part of Alnylam’s core product strategy &#8211; 5&#215;15 introduced ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Announces Share Buyback</title>
		<link>http://www.stockbloghub.com/2011/10/06/ew-edwards-lifesciences-announces-share-buyback/84653</link>
		<comments>http://www.stockbloghub.com/2011/10/06/ew-edwards-lifesciences-announces-share-buyback/84653#comments</comments>
		<pubDate>Thu, 06 Oct 2011 15:24:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84653</guid>
		<description><![CDATA[Edwards Lifesciences Corporation (EW) recently announced a new share repurchase program worth $500 million. At the end of the second quarter of fiscal 2011, the company was left with $240 million of authorization. Edwards expects to repurchase approximately $100 million worth of additional shares during the third quarter of the current fiscal. Edwards exited the second quarter of fiscal 2011 with $468.2 million in cash and cash equivalents (up from $396.1 million at the end of December 2010) and total debt of $174.8 million. Free cash flow generated during the quarter was $42.1 million and the company anticipates it to be within the $190?$200 million level for the year. Moreover, 970,000 shares for $83.2 million were repurchased during the most recent quarter. While the latest share buyback program is an ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/ew-edwards-lifesciences-announces-share-buyback/84653/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Sapien Under Centers for Medicare &amp; Medicaid Services NCA</title>
		<link>http://www.stockbloghub.com/2011/10/02/ew-edwards-lifesciences-sapien-under-centers-for-medicare-medicaid-services-nca/84430</link>
		<comments>http://www.stockbloghub.com/2011/10/02/ew-edwards-lifesciences-sapien-under-centers-for-medicare-medicaid-services-nca/84430#comments</comments>
		<pubDate>Sun, 02 Oct 2011 20:13:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>
		<category><![CDATA[STS]]></category>
		<category><![CDATA[Supreme Industries Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84430</guid>
		<description><![CDATA[Edwards Lifesciences (EW) received a major setback as the Centers for Medicare &#38; Medicaid Services (CMS) decided to initiate a National Coverage Analysis (NCA) of transcatheter aortic valve replacement (TAVR). As a result, the stock price of the company closed 6.58% lower on Thursday. According to the agency, it received a formal national coverage determination (NCD) request from the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC). Edwards, a leading player in the field of heart valves and hemodynamic monitoring, issued a statement regarding the matter. The company was aware that CMS was considering initiating an NCA to decide on the reimbursement status of Sapien transcatheter heart valve (THV). Besides, it believes that a well-written NCD should ultimately be positive for patients. Current investor focus is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/02/ew-edwards-lifesciences-sapien-under-centers-for-medicare-medicaid-services-nca/84430/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific Launches Coyote Balloon Catheter</title>
		<link>http://www.stockbloghub.com/2011/09/21/bsx-boston-scientific-launches-coyote-balloon-catheter/83704</link>
		<comments>http://www.stockbloghub.com/2011/09/21/bsx-boston-scientific-launches-coyote-balloon-catheter/83704#comments</comments>
		<pubDate>Wed, 21 Sep 2011 18:08:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83704</guid>
		<description><![CDATA[Boston Scientific Corporation (BSX) strengthened its Peripheral Interventions portfolio with the launch of Coyote Balloon catheter (0.014 inch) to treat patients undergoing peripheral angioplasty procedures below the knee. The company is marketing the product in the US, Europe and other international markets. Prior to this, in June, the company had launched Mustang percutaneous transluminal angioplasty (PTA) balloon catheter (0.035 inch) globally. Introduction of this device could prove beneficial to a huge patient population as according to estimates about 8?10 million patients in the US suffer from peripheral artery disease (PAD), giving way to blockage in vessels of the peripheral vasculature. In such cases, PTA balloon catheters come into play in peripheral angioplasty and stenting procedures to open up blocked arteries. Sales of this segment were $189 million in the second quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/bsx-boston-scientific-launches-coyote-balloon-catheter/83704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Grows Spinal Portfolio</title>
		<link>http://www.stockbloghub.com/2011/09/20/mdt-medtronic-grows-spinal-portfolio/83437</link>
		<comments>http://www.stockbloghub.com/2011/09/20/mdt-medtronic-grows-spinal-portfolio/83437#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:00:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AIS]]></category>
		<category><![CDATA[Antares Pharma Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83437</guid>
		<description><![CDATA[Leading medical devices player, Medtronic’s (MDT) TSRH Spinal System has received 510 (k) clearance from the US Food and Drug Administration (FDA) to treat adolescent idiopathic scoliosis (AIS) with pedicle screws. The system, developed in collaboration with Texas Scottish Rite Hospital (TSRH), offers several types of pedicle screws, implants and other instruments to stabilize the spine. AIS is the most common pediatric spine condition, where many patients have curved spines. Moreover, if curvature of the spine becomes more pronounced as the patient grows old; it could harm the spinal cord. TSRH and CD Horizon pedicle screws are meant for posterior use in addition to fusion in the thoracolumbar spine when treating AIS. Spinal is the second biggest segment at Medtronic that generated $825 million in sales, flat compared to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/mdt-medtronic-grows-spinal-portfolio/83437/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; Sept. 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743</link>
		<comments>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743#comments</comments>
		<pubDate>Thu, 08 Sep 2011 19:53:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82743</guid>
		<description><![CDATA[June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The highly-regulated medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/09/gb-greatbatch-analyst-reaffirms-shares-at-neutral/80927</link>
		<comments>http://www.stockbloghub.com/2011/08/09/gb-greatbatch-analyst-reaffirms-shares-at-neutral/80927#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:25:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80927</guid>
		<description><![CDATA[We reiterate our Neutral recommendation for Greatbatch Inc. (GB). Second-quarter fiscal 2011 earnings per share of 43 cents met the Zacks Consensus Estimate. Revenues rose 4% year over year to $146.5 million, topping the Zacks Consensus Estimate of $141 million. Sales were boosted by solid double-digit growth at the company’s Orthopedic franchise backed by favorable foreign exchange translation, which offset declines across other businesses. Greatbatch lifted its revenue and earnings forecast for the full year. Orthopedic revenues surged 24% in the quarter, fueled by customer product launches, market share gains as well as favorable foreign currency impact. Vascular Access sales fell 2% while CRM/Neuromodulation revenues edged down 1%, hurt by sustained pricing pressure and sluggishness in the CRM market. Revenues from Greatbatch’s Electrochem segment dipped 2% in the quarter. Greatbatch ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/gb-greatbatch-analyst-reaffirms-shares-at-neutral/80927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Gains &#8211; Earnings Miss Estimates</title>
		<link>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628</link>
		<comments>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628#comments</comments>
		<pubDate>Thu, 04 Aug 2011 15:47:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80628</guid>
		<description><![CDATA[Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during the quarter led to the surge in the company’s earnings. Revenues Quarterly revenues shot up 52.4% to $65.3 million, driven primarily by strong Ampyra sales. However, revenues marginally missed the Zacks Consensus Estimate of $67 million. Second quarter revenues comprised $62.9 million (up 55.3%) in product sales and $2.4 million (flat year over year) in license and royalty revenue. Sales of Ampyra, which was launched in March 2010, came in at $51.8 million, reflecting a year-over-year increase of 85%. Ampyra, aimed at improving walking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/04/acor-acorda-therapeutics-gains-earnings-miss-estimates/80628/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYBX) Cyberonics Stays Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/11/cybx-cyberonics-stays-neutral/78605</link>
		<comments>http://www.stockbloghub.com/2011/07/11/cybx-cyberonics-stays-neutral/78605#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:54:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78605</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Cyberonics (CYBX) with a target price of $30.00, following our assessment of its fourth quarter 2011 results. Cyberonics reported fourth quarter 2011 EPS of 26 cents, which missed the Zacks Consensus Estimate of 29 cents and were well below the year-ago quarter adjusted EPS of 40 cents. The year-over-year decline was attributable to significant increase in income tax expense ($5.5 million in the reported quarter compared with the year-ago quarter level of $.03 million). Cyberonics develops and markets Vagus Nerve Stimulation (VNS) Therapy System, which is approved by the US Food and Drug Administration (FDA) for the treatment of refractory epilepsy and treatment-resistant depression (TRD). During the quarter, Cyberonics witnessed a continuous expansion in its top line, attributable to the company’s pioneer product, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/cybx-cyberonics-stays-neutral/78605/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SRDX) SurModics Analysts Cut Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588</link>
		<comments>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588#comments</comments>
		<pubDate>Sun, 10 Jul 2011 18:17:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78588</guid>
		<description><![CDATA[We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson &#38; Johnson (JNJ) announced in June 2011 that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year-end. SurModics receives royalties on sales of the product. The news impacted SurModics’ shares negatively. We too have slashed our earnings estimate for fiscal 2012 by $0.08 per share. However, management at SurModics is not too perturbed by the recent development since royalties from the sales of Cypher stent have been on the decline due to reduced sales of the product. Sales of the product have been on the decline due to increased completion from players like Abbott Labs (ABT), Medtronic Inc. (MDT) and Boston Scientific Corporation (BSX). Global sales of Cypher during the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/10/srdx-surmodics-analysts-cut-shares-to-neutral/78588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACOR) Acorda Therapeutics Inks Deal with Medtronic</title>
		<link>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511</link>
		<comments>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:18:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[SCI]]></category>
		<category><![CDATA[Service Corporation International]]></category>
		<category><![CDATA[TBI]]></category>
		<category><![CDATA[TrueBlue Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78511</guid>
		<description><![CDATA[Acorda Therapeutics, Inc. (ACOR) recently entered into a licensing agreement with Medtronic, Inc. (MDT) for AC105. The company acquired worldwide development and commercialization rights to AC105. The Candidate – AC105 Acorda intends to study AC105 as an acute treatment for patients who have suffered neurological trauma, such as spinal cord injury (SCI) and traumatic brain injury (TBI). The candidate has demonstrated neuroprotective properties and improvement of locomotor function in SCI and cognitive function in TBI when therapy was initiated within four hours of injury in preclinical studies. Medtronic has evaluated the candidate in phase I studies conducted with healthy volunteers. Acorda intends to initially conduct phase II studies with the candidate for SCI. Other studies may subsequently be conducted for central nervous system indications like TBI and stroke. AC105 enjoys ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/acor-acorda-therapeutics-inks-deal-with-medtronic/78511/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Introduces Spinal Device</title>
		<link>http://www.stockbloghub.com/2011/07/06/mdt-medtronic-introduces-spinal-device/78477</link>
		<comments>http://www.stockbloghub.com/2011/07/06/mdt-medtronic-introduces-spinal-device/78477#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:30:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78477</guid>
		<description><![CDATA[Leading medical devices player, Medtronic (MDT), strengthened its Spinal portfolio with the launch of CD Horizon Fenestrated Screw Spinal System in Europe. The product will be used in combination with Fenestrated Screw Cement. Over the next few months, this product will be launched in India, Singapore and Australia. However, CD Horizon Fenestrated Screw Spinal System is not available in US. With CD Horizon Fenestrated Screw Spinal System, surgeons will be able to treat patients with poor bone quality that might arise from osteoporosis. Specially formulated bone cement can be injected into a patient’s vertebral body through the pedicle screw of the system that contains additional holes at the tip. During the last reported quarter, Medtronic’s Spinal segment generated $875 million in sales compared to $880 million in the year-ago period, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/mdt-medtronic-introduces-spinal-device/78477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BLUD) Company News for July 6, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433</link>
		<comments>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433#comments</comments>
		<pubDate>Wed, 06 Jul 2011 15:47:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[EE]]></category>
		<category><![CDATA[El Paso Electric Company]]></category>
		<category><![CDATA[Energy Transfer Equity L.P.]]></category>
		<category><![CDATA[ETE]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Oppenheimer Holdings Inc]]></category>
		<category><![CDATA[OPY]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[Southern Union Company]]></category>
		<category><![CDATA[SUG]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[Western Union Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[Williams Companies Inc.]]></category>
		<category><![CDATA[WMB]]></category>
		<category><![CDATA[WU]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78433</guid>
		<description><![CDATA[•    Share prices of Southern Union Co. (NYSE:SUG) rose 4.21% to close at $42.07 after Energy Transfer Equity, L.P. (NYSE:ETE) increased its bidding amount by 21% to $5 billion for the company, beating William&#8217;s (NYSE:WMB) bid of $4.9 billion •    U.S. mining giant Peabody Energy Corp. (NYSE:BTU) was amongst a consortium selected by the  Mongolian Government  to develop the Tavan Tolgoi  coal mining project in the Gobi Desert •    Analysts of Wells Fargo (NYSE:WFC) opined that a medical journal report about Medtronic’s (NYSE:MDT) spine device will slow down sales. The report could also lead to investigations by federal regulators •    Analysts at Oppenheimer &#38; Co. (NYSE:OPY) initiated coverage on shares of Zalicus, Inc. (NASDAQ:ZLCS) with an &#8220;Outperform&#8221; rating and a target price of $4.00 •    Shares of Immucor, Inc. (NASDAQ:BLUD) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/blud-company-news-for-july-6-2011-corporate-summary/78433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Expands Kyphon Portfolio</title>
		<link>http://www.stockbloghub.com/2011/07/03/mdt-medtronic-expands-kyphon-portfolio/78278</link>
		<comments>http://www.stockbloghub.com/2011/07/03/mdt-medtronic-expands-kyphon-portfolio/78278#comments</comments>
		<pubDate>Sun, 03 Jul 2011 19:25:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78278</guid>
		<description><![CDATA[Recently, Medtronic (MDT) launched two products to add to the Kyphon Balloon Kyphoplasty procedure (BKP), which is used for treating vertebral compression fractures (VCFs). The products are Kyphon Xpander II Inflatable Bone Tamp (IBT) and the Kyphon Inflation Syringe &#8211; the Kyphon Xpander II IBT System. The Kyphon Xpander II IBT System has been in use since November 2010. During the last reported quarter, revenues from BKP declined 9% (5% decline in the third quarter) and were flat on a sequential basis. In February 2011, results from three BKP studies were published that demonstrated the benefits of this technology Medtronic is confident of recording higher revenues from BKP in the forthcoming period based on positive coverage decision issued by Noridian Administrative Services in May. Moreover, data presented over the last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/03/mdt-medtronic-expands-kyphon-portfolio/78278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic&#8217;s Bone Protein in Controversy</title>
		<link>http://www.stockbloghub.com/2011/06/30/mdt-medtronics-bone-protein-in-controversy/77970</link>
		<comments>http://www.stockbloghub.com/2011/06/30/mdt-medtronics-bone-protein-in-controversy/77970#comments</comments>
		<pubDate>Thu, 30 Jun 2011 21:28:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77970</guid>
		<description><![CDATA[Leading medical devices player Medtronic (MDT) has been put under the scanner based on some articles published on recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in a recent edition of Spine Journal. According to a report issued in The Wall Street Journal (WSJ) on the Spine Journal finding, surgeons missed to mention the complications encountered with bone-growth protein in clinical trials. The WSJ reported that the Spine Journal found many serious complications such as sterility, infection, bone dissolution and worsened back and leg pain as well as cancer in 10-50% of patients who were treated with Infuse or a sister product in 13 clinical trials. These trials were funded by Medtronic and conducted by the surgeons during 2000 and 2010. Infuse Bone Graft constitutes rhBMP-2, which is applied to an absorbable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/mdt-medtronics-bone-protein-in-controversy/77970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Actively Checks Diabetes</title>
		<link>http://www.stockbloghub.com/2011/06/27/mdt-medtronic-actively-checks-diabetes/77602</link>
		<comments>http://www.stockbloghub.com/2011/06/27/mdt-medtronic-actively-checks-diabetes/77602#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:51:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77602</guid>
		<description><![CDATA[In a positive development, research findings presented at a recent conference mirrors the effectiveness of Medtronic’s (MDT) insulin pump therapy for improved glucose control in type 1 diabetic patients. The company offers sensor-augmented insulin pump therapy that integrates continuous glucose monitoring (CGM) into one device. In the fourth quarter of fiscal 2011, revenues from Medtronic’s Diabetes segment increased 11% year over year (9% at CER) to $368 million driven by 20% growth in CGM sales and robust growth in global insulin pumps. Both its Veo and Revel pumps continued to perform well. During the last reported quarter, Medtronic launched the Enlite Sensor in more than 35 countries outside the US and expects it to drive growth in the CGM business in fiscal 2012. The product is an advanced glucose sensor ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/mdt-medtronic-actively-checks-diabetes/77602/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Device Reducing Migraines</title>
		<link>http://www.stockbloghub.com/2011/06/26/stj-st-jude-medical-device-reducing-migraines/77473</link>
		<comments>http://www.stockbloghub.com/2011/06/26/stj-st-jude-medical-device-reducing-migraines/77473#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:24:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77473</guid>
		<description><![CDATA[Medical devices major St. Jude Medical (STJ) presented encouraging results from a large-scale clinical study evaluating the effectiveness of an implantable device developed by the company in treating chronic migraine, a condition afflicting millions globally. Migraines are estimated to affect roughly 28 million Americans. It is a debilitating condition which can last for hours or days. Migraine is characterized by symptoms such as headache, sensitivity to light, noise and motion, nausea and vomiting. Chronic migraine represents a vastly unmet medical need. The company-sponsored study, which was presented at the International Headache Congress in Berlin, Germany, demonstrated that peripheral nerve stimulation (“PNS”) of the occipital nerve using the company’s implanted device was safe and effective in reducing the number of migraine headache days per month and helped improve patient quality of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/stj-st-jude-medical-device-reducing-migraines/77473/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Announces Increase in Dividend</title>
		<link>http://www.stockbloghub.com/2011/06/26/mdt-medtronic-announces-increase-in-dividend/77487</link>
		<comments>http://www.stockbloghub.com/2011/06/26/mdt-medtronic-announces-increase-in-dividend/77487#comments</comments>
		<pubDate>Sun, 26 Jun 2011 16:41:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77487</guid>
		<description><![CDATA[Recently, Medtronic’s (MDT) Board approved a hike in the company’s quarterly dividend to 24.25 cents per share from the current payout of 22.50 cents. This will result in an 8% increase in the company’s annual dividend to 97 cents. The revised dividend is payable on July 29, 2011, to shareholders of record as of July 8. The move represents the 34th consecutive year of dividend increase by Medtronic and marks the strength of the company’s business model, reflecting its commitment to return value to shareholders with its strong cash generation capabilities. Separately, Medronic also decided to boost its share repurchase plan. The company’s Board has cleared an additional 75 million of shares to its repurchase program which represents approximately 7% of its outstanding stock. Over the past six years, Medronic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/mdt-medtronic-announces-increase-in-dividend/77487/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Devices Get Japanese Nod</title>
		<link>http://www.stockbloghub.com/2011/06/24/stj-st-jude-devices-get-japanese-nod/77344</link>
		<comments>http://www.stockbloghub.com/2011/06/24/stj-st-jude-devices-get-japanese-nod/77344#comments</comments>
		<pubDate>Fri, 24 Jun 2011 15:58:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77344</guid>
		<description><![CDATA[Medical technology giant St. Jude Medical (STJ) has received clearance of the Japanese Ministry of Health, Labor and Welfare (“MHLW”) for its Fortify ST implantable cardioverter defibrillator (“ICD”) and Unify cardiac resynchronization therapy defibrillator (“CRT-D”). The Minnesota-based company has launched these products, the smallest available in the industry, in the lucrative Japanese market. ICDs treat abnormally fast heartbeats, which can lead to sudden cardiac arrest &#8211; a risk to life. CRT-Ds resynchronize the beating of the heart’s lower chambers that often beat abnormally in patients with heart failure. Fortify ST ICD and Unify CRT-D feature advanced battery technology and circuitry along with more energy capacity and rapid charge times while having extended longevity. These devices also feature 40J of delivered energy, which ensures that treatment will be successful for patients ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/stj-st-jude-devices-get-japanese-nod/77344/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179#comments</comments>
		<pubDate>Thu, 23 Jun 2011 01:09:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77179</guid>
		<description><![CDATA[A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices industry continues to grow at a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medical-devices-stock-outlook-june-2011-industry-outlook/77179/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Stent Found Safe</title>
		<link>http://www.stockbloghub.com/2011/06/22/mdt-medtronic-stent-found-safe/76851</link>
		<comments>http://www.stockbloghub.com/2011/06/22/mdt-medtronic-stent-found-safe/76851#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:19:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76851</guid>
		<description><![CDATA[Leading medical devices player Medtronic (MDT) presented positive results for Valiant thoracic stent graft system after one-year patient follow-up in the US pivotal study, VALOR II, involving 160 patients. The data was presented at the annual meeting of the Society for Vascular Surgery. It was observed that Valiant stent graft is a safe and effective treatment for patients with descending thoracic aortic aneurysm (TAA) of degenerative etiology. TAA entails dangerous swelling in the body’s main artery, which if ruptures usually results in death. As per estimates, about 60,000 people in the US suffer from TAA. Treatment with stent graft or invasive surgery is possible if the condition is detected early. According to the principal investigator, Dr. Ronald Fairman, during the 12-month study period, there were no cases of rupture or ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/mdt-medtronic-stent-found-safe/76851/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Unit Sues Occlutech</title>
		<link>http://www.stockbloghub.com/2011/06/20/stj-st-jude-medical-unit-sues-occlutech/76837</link>
		<comments>http://www.stockbloghub.com/2011/06/20/stj-st-jude-medical-unit-sues-occlutech/76837#comments</comments>
		<pubDate>Tue, 21 Jun 2011 04:21:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76837</guid>
		<description><![CDATA[Medical devices major St. Jude Medical (STJ) reported that its subsidiary AGA Medical Holdings has filed new patent infringement lawsuits against Europe-based cardiac occlusion (closure) devices and vascular implants maker Occlutech. The suits, which were filed at the District Court of Duesseldorf, Germany, and the High Court of Justice, Chancery Division (Patents Court), U.K., involve three patents and seek injunctive relief and monetary compensation. Minnesota-based heart devices maker AGA Medical Holdings has been involved in litigation with Occlutech since 2006. The latest lawsuits allege that Occlutech’s  atrial septal defect (“ASD”) and patent foramen ovale (“PFO”) closure/occlusion devices infringe key patents used in St. Jude Medical AMPLATZER occlusion device platform. The platform offers minimally invasive transcatheter treatments for the safe closure of structural heart defects. Occlutech received a favorable ruling from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/stj-st-jude-medical-unit-sues-occlutech/76837/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NURO) NeuroMetrix Partners for Diabetes</title>
		<link>http://www.stockbloghub.com/2011/06/20/nuro-neurometrix-partners-for-diabetes/76607</link>
		<comments>http://www.stockbloghub.com/2011/06/20/nuro-neurometrix-partners-for-diabetes/76607#comments</comments>
		<pubDate>Mon, 20 Jun 2011 16:18:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Neurometrix Inc]]></category>
		<category><![CDATA[NURO]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76607</guid>
		<description><![CDATA[Nerve testing devices maker NeuroMetrix (NURO) has partnered with Florida-based leading diabetes management products maker Nipro Diagnostics for its latest test, the NC-stat DPNCheck. The NC-stat DPNCheck test has been designed for evaluating systemic neuropathies such as diabetic peripheral neuropathy (“DPN”). Nipro Diagnostics, a wholly-owned subsidiary of Japan-based Nipro Corporation Inc, offers high-quality blood glucose monitoring products and systems globally. The collaboration (between NeuroMetrix and Nipro) will focus on evaluating the opportunities for the novel NC-stat DPNCheck test in the rapidly growing retail medical clinic market. DPN, a common and serious complication of diabetes, affects roughly 60%-70% of diabetics and may lead to foot ulcers and amputations. Currently, there is a lack of standardized test for DPN at the point-of-care, triggering a large unmet need. NC-stat DPNCheck is a modified ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/nuro-neurometrix-partners-for-diabetes/76607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GOOG) Seeking Yield from Stocks Instead of Bonds &#8211; AAII Investor Update</title>
		<link>http://www.stockbloghub.com/2011/05/23/goog-seeking-yield-from-stocks-instead-of-bonds-aaii-investor-update/74612</link>
		<comments>http://www.stockbloghub.com/2011/05/23/goog-seeking-yield-from-stocks-instead-of-bonds-aaii-investor-update/74612#comments</comments>
		<pubDate>Mon, 23 May 2011 14:04:39 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Internet Information Providers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AEE]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Altria Group Inc.]]></category>
		<category><![CDATA[Ameren Corporation]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[CDR]]></category>
		<category><![CDATA[Cedar Shopping Centers Inc.]]></category>
		<category><![CDATA[Centurytel Inc.]]></category>
		<category><![CDATA[CINF]]></category>
		<category><![CDATA[Cinnati Financial Corporation]]></category>
		<category><![CDATA[CLI]]></category>
		<category><![CDATA[COST]]></category>
		<category><![CDATA[Costco Wholesale Corporation]]></category>
		<category><![CDATA[CTL]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[DUK]]></category>
		<category><![CDATA[Duke Energy Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Entertainment Properties Trust]]></category>
		<category><![CDATA[EPR]]></category>
		<category><![CDATA[EXC]]></category>
		<category><![CDATA[Exelon Corporation]]></category>
		<category><![CDATA[FE]]></category>
		<category><![CDATA[Firstenergy Corporation]]></category>
		<category><![CDATA[Franklin Street Properties Corporation]]></category>
		<category><![CDATA[Frontier Communications Corporation]]></category>
		<category><![CDATA[FSP]]></category>
		<category><![CDATA[FTR]]></category>
		<category><![CDATA[Getty Realty Corporation]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[GTY]]></category>
		<category><![CDATA[HCN]]></category>
		<category><![CDATA[HCP]]></category>
		<category><![CDATA[HCP Inc.]]></category>
		<category><![CDATA[Health Care REIT Inc]]></category>
		<category><![CDATA[Healthcare Realty Trust Inc]]></category>
		<category><![CDATA[HJ Heinz Company]]></category>
		<category><![CDATA[HNZ]]></category>
		<category><![CDATA[HR]]></category>
		<category><![CDATA[Inland Real Estate Corporation]]></category>
		<category><![CDATA[Integrys Energy Group Inc.]]></category>
		<category><![CDATA[IRC]]></category>
		<category><![CDATA[iShares S&P 1500 Index]]></category>
		<category><![CDATA[ISI]]></category>
		<category><![CDATA[Liberty Property Trust]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[LRY]]></category>
		<category><![CDATA[LTC]]></category>
		<category><![CDATA[LTC Properties Inc.]]></category>
		<category><![CDATA[Mack-Cali Realty Corporation]]></category>
		<category><![CDATA[MCY]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medical Properties Trust Inc]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Mercury General Corporation]]></category>
		<category><![CDATA[MO]]></category>
		<category><![CDATA[MPW]]></category>
		<category><![CDATA[National Oilwell Varco Incorporated]]></category>
		<category><![CDATA[National Retail Properties Inc]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[NNN]]></category>
		<category><![CDATA[Norfolk Southern Corporation]]></category>
		<category><![CDATA[NOV]]></category>
		<category><![CDATA[NSC]]></category>
		<category><![CDATA[NTELOS Holdings Corporation]]></category>
		<category><![CDATA[NTLS]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[OHI]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[Omega Healthcare Investors Inc]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[OSG]]></category>
		<category><![CDATA[Overseas Shipholding Group Inc]]></category>
		<category><![CDATA[PBI]]></category>
		<category><![CDATA[PCH]]></category>
		<category><![CDATA[Pepco Holdings Inc.]]></category>
		<category><![CDATA[PGN]]></category>
		<category><![CDATA[Pitney Bowes Inc.]]></category>
		<category><![CDATA[POM]]></category>
		<category><![CDATA[Potlatch Corporation]]></category>
		<category><![CDATA[PPL]]></category>
		<category><![CDATA[PPL Corporation]]></category>
		<category><![CDATA[Progress Energy Inc.]]></category>
		<category><![CDATA[Prospect Capital Corporation]]></category>
		<category><![CDATA[PSEC]]></category>
		<category><![CDATA[R.R. Donnelley & Sons Company]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[RRD]]></category>
		<category><![CDATA[Senior Housing Properties Trust]]></category>
		<category><![CDATA[SNH]]></category>
		<category><![CDATA[SR]]></category>
		<category><![CDATA[Standard Register Company]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[TEG]]></category>
		<category><![CDATA[UBA]]></category>
		<category><![CDATA[UHT]]></category>
		<category><![CDATA[UIL]]></category>
		<category><![CDATA[UIL Holdings Corporation]]></category>
		<category><![CDATA[United Online Inc.]]></category>
		<category><![CDATA[Universal Health Realty Income Trust]]></category>
		<category><![CDATA[UNTD]]></category>
		<category><![CDATA[Urstadt Biddle Properties Inc]]></category>
		<category><![CDATA[USA Mobility Inc]]></category>
		<category><![CDATA[USMO]]></category>
		<category><![CDATA[Valley National Bancorp]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VLY]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Walt Disney Company]]></category>
		<category><![CDATA[WIBC]]></category>
		<category><![CDATA[Wilshire Bancorp Inc]]></category>
		<category><![CDATA[WIN]]></category>
		<category><![CDATA[Windstream Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74612</guid>
		<description><![CDATA[Income-oriented investors have yet another reason to be upset with the bond markets. Junk bond yields fell to a record low a few days ago and are staying near those levels. As of Wednesday evening, the Barclays U.S. Corporate High Yield index yielded a mere 6.68%, which isn&#8217;t much when you consider the risk of default. These low yields are just one sign of the bond market&#8217;s cheery mood. Corporations are finding plenty of buyers for their debt, and many offerings have been completed this week. Among the investment-grade companies selling bonds are Google (GOOG), Norfolk Southern (NSC) and Walt Disney (DIS). Included in this week&#8217;s near-record level of junk bond offerings is beleaguered Chrysler, which is refinancing its loan package. Taking advantage of the low interest rates is good ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/23/goog-seeking-yield-from-stocks-instead-of-bonds-aaii-investor-update/74612/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(USB) U.S. Trade Deficit Up on Foreign Oil Addiction</title>
		<link>http://www.stockbloghub.com/2011/05/11/usb-u-s-trade-deficit-up-on-foreign-oil-addiction/73858</link>
		<comments>http://www.stockbloghub.com/2011/05/11/usb-u-s-trade-deficit-up-on-foreign-oil-addiction/73858#comments</comments>
		<pubDate>Thu, 12 May 2011 00:47:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Regional - Midwest Banks]]></category>
		<category><![CDATA[APA]]></category>
		<category><![CDATA[Apache Corporation]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[commodities]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[NG]]></category>
		<category><![CDATA[NovaGold Resources Inc]]></category>
		<category><![CDATA[SI]]></category>
		<category><![CDATA[Siemens AG]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73858</guid>
		<description><![CDATA[The Trade Deficit rose in March to $48.18 billion from $45.44 billion in January (revised down from $45.76 billion. The rise in the trade deficit is bad news for the economy, and the level is very dangerous. For the month it was up 6.0%, and it was worse than the $47.7 billion consensus expectation. On a year-over-year basis, the total trade deficit was up 21.9% from $39.51 billion a year ago. The trade balance has two major parts: trade in goods and trade in services. America’s problem is always on the goods side; we actually routinely have a small surplus in services. Relative to February, the goods deficit rose to $62.11 billion from $59.10 billion. That is a month-to-month increase of 5.1%. Relative to a year ago, the goods deficit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/usb-u-s-trade-deficit-up-on-foreign-oil-addiction/73858/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

